Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical costs, a trend that’s concerned investors in the sector for months.

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over prescription drug costs.

After UnitedHealthcare CEO Brian Thompson was shot to death in December, law enforcement records show a burst of police activity at the homes of health executives.

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite surges for obesity drugmakers Eli Lilly and Novo Nordisk. But the sector is off to a healthy start in 2025.

People with Cigna health insurance who receive care at CRMC, Clovis Community and affiliated doctors could face disruptions.

Express Scripts aims to ensure that patients directly benefit from its negotiations with drug manufacturers. The new approach will protect patients from paying inflated list prices for medications, instead providing them with the lower prices negotiated by the PBM, according to a Jan. 29 news release from the company.

TD Cowen analyst Ryan Langston maintained a Buy rating on Cigna (CI – Research Report) today and set a price target of $391.00. The company’s

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

CVS Health (CVS) on Tuesday announced the launch of the CVS Health app. The app, a successor to the CVS Pharmacy app and one of many

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.3 billion in “excess” revenue over ...